AppetiteNCT07757438
Effects of Home-Based Transcranial Direct Current Stimulation on Appetite
A study testing Active Home-Based tDCS in people with Appetite and Binge Eating Behaviour, run by Seoul National University Hospital.
Trial summary
This randomized, placebo-controlled, double-blind, parallel-design study aims to evaluate the neurophysiological effects of home-based transcranial direct current stimulation (tDCS) on appetite in adults with binge eating tendencies. Read more about this study
- Who is it for?
- Ages 19 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Appetite, Binge Eating Behaviour, Food Cravings
- What is being tested?
- Active Home-Based tDCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 Aug 2026to 30 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 19 to 65 years
- Binge Eating Scale (BES) score ≥18
- BMI ≥18.5 kg/m²
- No significant weight loss or lifestyle changes during the previous 3 months
- Stable chronic medical conditions (e.g., hypertension, diabetes, dyslipidemia) are allowed
- Able to use an Android smartphone compatible with the study application (including a study phone if provided)
- Able and willing to provide written informed consent
Who cannot join
- Unable to understand the study procedures or provide informed consent
- Implanted pacemaker, implantable cardioverter-defibrillator, deep brain stimulator, cochlear implant, coronary stent, or other implanted metallic medical devices (dental implants and joint prostheses are allowed)
- Diagnosis or treatment for a psychiatric or neurological disorder within the previous 3 months
- Use of medications affecting appetite or body weight within the previous month
- Use of medications affecting eating behavior or mood within the previous month
- Pregnant or breastfeeding
- Any medical condition judged by the investigator to interfere with study participation or interpretation of study results
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Neurophysiological Effects of Transcranial Direct Current Stimulation on Appetite: Randomized, Placebo-Controlled, Double-Blind, Parallel-Design
This randomized, placebo-controlled, double-blind, parallel-design study aims to evaluate the neurophysiological effects of home-based transcranial direct current stimulation (tDCS) on appetite in adults with binge eating tendencies.
Participants will be randomly assigned to either an active tDCS group or a sham stimulation group. After baseline assessments, participants will self-administer home-based tDCS twice daily for 4 weeks using a wearable wellness device. Appetite, eating behavior, body composition, dietary intake, and psychological outcomes will be assessed throughout the study to evaluate both the acute and chronic effects of repeated tDCS.
Read the detailed description
Obesity and binge eating behaviors are closely associated with abnormal appetite regulation and food craving. Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation technique that may modulate prefrontal cortical activity involved in appetite control and inhibitory regulation.
The objective of this study is to investigate whether repeated home-based tDCS reduces appetite and improves eating-related behaviors in adults with binge eating tendencies.
This study is a randomized, placebo-controlled, double-blind, parallel-design trial. A total of 100 participants aged 19 to 65 years with Binge Eating Scale (BES) scores of 18 or higher will be enrolled and randomized in a 1:1 ratio to either an active tDCS group or a sham stimulation group.
Participants will perform home-based tDCS twice daily for 4 weeks using a wearable wellness scalp stimulation device. Appetite will be evaluated using repeated visual analogue scale (VAS) assessments to examine both acute and chronic effects of stimulation. Secondary outcome measures include changes in body composition, eating behavior questionnaires, food craving, binge eating severity, dietary intake, sleep quality, stress, depression, and anxiety.
The findings of this study are expected to provide evidence regarding the neurophysiological effects of repeated home-based tDCS on appetite regulation and eating behavior.
- Conditions
- Appetite, Binge Eating Behaviour, Food Cravings
- Being tested
- Active Home-Based tDCS, Sham Home-Based tDCS
- Keywords
- Transcranial Direct Current Stimulation, tDCS, Appetite, Food Craving, Binge Eating, Eating Behavior, Home-based Intervention, Neuromodulation
- Medical subject headings
- Binge-Eating Disorder, Bulimia, Feeding Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active Home-Based tDCSDevice
Participants receive active home-based transcranial direct current stimulation (tDCS) using a wearable wellness scalp stimulation device. Active stimulation delivers 1.0 mA direct current for 20 minutes twice daily for 4 weeks.
Sham Home-Based tDCSDevice
Participants receive sham home-based transcranial direct current stimulation (tDCS) using the same wearable wellness scalp stimulation device. Sham stimulation delivers brief current only at the beginning and end of each session to maintain blinding.
| Study group | Role | What they receive |
|---|---|---|
| Active tDCS | Experimental | Participants receive active home-based transcranial direct current stimulation (tDCS) using a wearable wellness scalp stimulation device. Active stimulation delivers 1.0 mA direct current for 20 minutes twice daily for 4 weeks. Receives: Device: Active Home-Based tDCS |
| Sham tDCS | Sham comparator | Participants receive sham home-based transcranial direct current stimulation (tDCS) using the same wearable wellness scalp stimulation device. Sham stimulation delivers brief current only at the beginning and end of each session to maintain blinding. Receives: Device: Sham Home-Based tDCS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Appetite Visual Analog Scale Score Before and After Stimulation
Acute change in appetite is assessed using the Appetite Visual Analog Scale (VAS) immediately before and after the first daily stimulation session on Days 7, 14, 21, and 28. The acute effect is defined as the change in Appetite VAS score from immediately before to immediately after stimulation. The Appetite Visual Analog Scale ranges from 0 to 10, with higher scores indicating greater appetite.
Measured: Immediately before and after the first stimulation session on Days 7, 14, 21, and 28.
Change in Bedtime Appetite Visual Analog Scale Score Over 4 Weeks
Chronic change in appetite is assessed using the bedtime Appetite Visual Analog Scale (BT-VAS), measured once daily before bedtime from Day 1 through Day 28. The chronic effect is evaluated based on the change in bedtime Appetite VAS scores over time during the 4-week intervention period. The Appetite Visual Analog Scale ranges from 0 to 10, with higher scores indicating greater appetite.
Measured: Daily from Day 1 through Day 28
Secondary outcomes (21)
Change in Body Weight
Change in body weight measured in kilograms (kg) from baseline to Week 4.
Measured: Baseline to Week 4
Change in Body Mass Index
Change in body mass index (BMI), calculated as body weight in kilograms divided by height in meters squared (kg/m²), from baseline to Week 4.
Measured: Baseline to Week 4
Change in Body Fat Percentage
Change in body fat percentage, measured as a percentage (%), from baseline to Week 4.
Measured: Baseline to Week 4
Change in Waist Circumference
Change in waist circumference measured in centimeters (cm) from baseline to Week 4.
Measured: Baseline to Week 4
Change in Skeletal Muscle Mass
Change in skeletal muscle mass measured in kilograms (kg) using bioelectrical impedance analysis from baseline to Week 4.
Measured: Baseline to Week 4
Change in Dutch Eating Behavior Questionnaire Scores
The Dutch Eating Behavior Questionnaire (DEBQ) assesses restrained, emotional, and external eating behavior using 33 items rated on a 5-point scale. The restrained eating subscale consists of 10 items, yielding a total score ranging from 10 to 50; higher scores indicate greater dietary restraint and stronger conscious control of food intake. The emotional eating subscale consists of 13 items, yielding a total score ranging from 13 to 65; higher scores indicate a greater tendency to eat in response to emotional states. The external eating subscale consists of 10 items, yielding a total score ranging from 10 to 50; higher scores indicate a greater tendency to eat in response to external food-related cues. Changes in the three DEBQ subscale scores will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Reward-Based Eating Drive Scale Score
The Reward-Based Eating Drive Scale-13 (RED-13) assesses reward-based eating, including loss of control over eating, lack of satiety, and preoccupation with food. The 13 items are rated from 1 to 5 and summed to yield a total score ranging from 10 to 65. Higher scores indicate greater reward-based eating drive. Change in RED-13 total score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in General Food Cravings Questionnaire-Trait Score
The General Food Cravings Questionnaire-Trait (G-FCQ-T) assesses trait-like general food craving. It consists of 21 items rated from 1 to 6, yielding a total score ranging from 21 to 126. Higher scores indicate greater trait food craving. Change in G-FCQ-T total score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
General Food Cravings Questionnaire-State Score
The General Food Cravings Questionnaire-State (G-FCQ-S) assesses current or momentary food craving. It consists of 15 items rated on a 5-point scale from 1 to 5, yielding a total score ranging from 15 to 75. Higher scores indicate greater current food craving. G-FCQ-S scores will be assessed repeatedly on Days 7, 14, 21, and 28 during the 4-week intervention period.
Measured: Days 7, 14, 21, and 28
Change in Behavioral Inhibition System Score
The Behavioral Inhibition System (BIS) scale consists of 7 items rated on a 4-point scale from 1 to 4, yielding a total score ranging from 7 to 28. Higher scores indicate greater sensitivity to punishment and stronger behavioral inhibition. Change in the BIS score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Behavioral Activation System Scores
The Behavioral Activation System (BAS) scale consists of 13 items rated on a 4-point scale from 1 to 4 and comprises three subscales: Reward Responsiveness (5 items; score range, 5-20), Drive (4 items; score range, 4-16), and Fun Seeking (4 items; score range, 4-16). Higher scores indicate greater reward responsiveness, stronger goal-directed drive, and greater fun-seeking tendency, respectively. Changes in the BAS subscale scores will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Eating Expectancy Inventory (EEI) Scores
The Korean version of the Eating Expectancy Inventory (EEI) assesses expectancies regarding the psychological and emotional consequences of eating. The questionnaire consists of 28 items rated on a 7-point Likert scale from 1 to 7, yielding a total score ranging from 28 to 196. Higher scores indicate stronger endorsement of eating-related expectancies. Change in the EEI total score will be assessed from baseline to Week 4.
Measured: Baseline and Week 4
Change in Anticipated Negative Effects of Junk Food Score
The Korean version of the Anticipated Effects of Food Scale (AEFS) assesses anticipated emotional responses to eating food. The negative affect subscale for junk food consists of 12 items rated from 1 to 6, yielding a total score ranging from 12 to 72. Higher scores indicate stronger anticipated negative emotional effects of eating junk food. Change in the subscale score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Anticipated Positive Effects of Junk Food Score
The Korean version of the Anticipated Effects of Food Scale (AEFS) assesses anticipated emotional responses to eating food. The positive affect subscale for junk food consists of 12 items rated from 1 to 6, yielding a total score ranging from 12 to 72. Higher scores indicate stronger anticipated positive emotional effects of eating junk food. Change in the subscale score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Anticipated Negative Effects of Healthy Food Score
The Korean version of the Anticipated Effects of Food Scale (AEFS) assesses anticipated emotional responses to eating food. The negative affect subscale for healthy food consists of 12 items rated from 1 to 6, yielding a total score ranging from 12 to 72. Higher scores indicate stronger anticipated negative emotional effects of eating healthy food. Change in the subscale score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Anticipated Positive Effects of Healthy Food Score
The Korean version of the Anticipated Effects of Food Scale (AEFS) assesses anticipated emotional responses to eating food. The positive affect subscale for healthy food consists of 12 items rated from 1 to 6, yielding a total score ranging from 12 to 72. Higher scores indicate stronger anticipated positive emotional effects of eating healthy food. Change in the subscale score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Perceived Stress Scale Score
The Perceived Stress Scale (PSS) assesses the degree to which situations in one's life are perceived as stressful. For the 10-item version (PSS-10), items are scored from 0 to 4 and summed after reverse scoring the positively stated items, yielding a total score ranging from 0 to 40. Higher scores indicate greater perceived stress. Change in PSS total score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Pittsburgh Sleep Quality Index Score
The Pittsburgh Sleep Quality Index (PSQI) assesses subjective sleep quality and disturbances. Seven component scores are summed to yield a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality and greater sleep disturbance. Change in PSQI global score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Beck Depression Inventory-II Score
The Beck Depression Inventory-II (BDI-II) assesses the severity of depressive symptoms. The 21 items are scored from 0 to 3 and summed to yield a total score ranging from 0 to 63. Higher scores indicate greater severity of depressive symptoms. Change in BDI-II total score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Beck Anxiety Inventory Score
The Beck Anxiety Inventory (BAI) assesses the severity of anxiety symptoms. The 21 items are scored from 0 to 3 and summed to yield a total score ranging from 0 to 63. Higher scores indicate greater severity of anxiety symptoms. Change in BAI total score will be assessed from baseline to Week 4.
Measured: Baseline to Week 4
Change in Binge Eating Scale Score
The Binge Eating Scale (BES) assesses the severity of binge eating symptoms and associated thoughts and behaviors. The scale consists of 16 items, with item responses assigned weighted scores ranging from 0 to 3. The total score ranges from 0 to 46, with higher scores indicating greater severity of binge eating symptoms. Change in the BES total score will be assessed from screening to Week 4.
Measured: Screening to Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2026
- Study start15 Aug 2026 (estimated)
- Primary completion31 Mar 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AppetiteStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hyung Jin Choi, Seoul National University Hospital
- Investigators
- Hyung jin Choi, MD-PhD, Principal investigator, Seoul National University College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07757438
- Sponsor's protocol ID
- DCS26-SNU
- Status last verified
- Aug 2026
- First submitted
- 3 Aug 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared because there is no current plan for public or external data sharing. De-identified study data will be used only for the purposes described in the study protocol and approved by the Institutional Review Board (IRB).
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neurophysiological Effects of Transcranial Direct Current Stimulation on Appetite: Randomized, Placebo-Controlled, Double-Blind, Parallel-Design
- ClinicalTrials.gov ID
- NCT07757438
- Acronym / sponsor ID
- DCS26-SNU
- Conditions
- Appetite, Binge Eating Behaviour, Food Cravings
- Keywords
- Transcranial Direct Current Stimulation, tDCS, Appetite, Food Craving, Binge Eating, Eating Behavior, Home-based Intervention, Neuromodulation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Study start
- 15 Aug 2026 (estimated)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 11 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, placebo-controlled, double-blind, parallel-design study aims to evaluate the neurophysiological effects of home-based transcranial direct current stimulation (tDCS) on appetite in adults with binge eating tendencies.
Participants will be randomly assigned to either an active tDCS group or a sham stimulation group. After baseline assessments, participants will self-administer home-based tDCS twice daily for 4 weeks using a wearable wellness device. Appetite, eating behavior, body composition, dietary intake, and psychological outcomes will be assessed throughout the study to evaluate both the acute and chronic effects of repeated tDCS.
Detailed description
Obesity and binge eating behaviors are closely associated with abnormal appetite regulation and food craving. Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation technique that may modulate prefrontal cortical activity involved in appetite control and inhibitory regulation.
The objective of this study is to investigate whether repeated home-based tDCS reduces appetite and improves eating-related behaviors in adults with binge eating tendencies.
This study is a randomized, placebo-controlled, double-blind, parallel-design trial. A total of 100 participants aged 19 to 65 years with Binge Eating Scale (BES) scores of 18 or higher will be enrolled and randomized in a 1:1 ratio to either an active tDCS group or a sham stimulation group.
Participants will perform home-based tDCS twice daily for 4 weeks using a wearable wellness scalp stimulation device. Appetite will be evaluated using repeated visual analogue scale (VAS) assessments to examine both acute and chronic effects of stimulation. Secondary outcome measures include changes in body composition, eating behavior questionnaires, food craving, binge eating severity, dietary intake, sleep quality, stress, depression, and anxiety.
The findings of this study are expected to provide evidence regarding the neurophysiological effects of repeated home-based tDCS on appetite regulation and eating behavior.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active tDCS | Experimental | Device: Active Home-Based tDCSParticipants receive active home-based transcranial direct current stimulation (tDCS) using a wearable wellness scalp stimulation device. Active stimulation delivers 1.0 mA direct current for 20 minutes twice daily for 4 weeks. |
| Sham tDCS | Sham comparator | Device: Sham Home-Based tDCSParticipants receive sham home-based transcranial direct current stimulation (tDCS) using the same wearable wellness scalp stimulation device. Sham stimulation delivers brief current only at the beginning and end of each session to maintain blinding. |
Who may qualify
- Ages
- 19 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults aged 19 to 65 years
- Binge Eating Scale (BES) score ≥18
- BMI ≥18.5 kg/m²
- No significant weight loss or lifestyle changes during the previous 3 months
- Stable chronic medical conditions (e.g., hypertension, diabetes, dyslipidemia) are allowed
Key exclusion criteria (7 listed)
- Unable to understand the study procedures or provide informed consent
- Implanted pacemaker, implantable cardioverter-defibrillator, deep brain stimulator, cochlear implant, coronary stent, or other implanted metallic medical devices (dental implants and joint prostheses are allowed)
- Diagnosis or treatment for a psychiatric or neurological disorder within the previous 3 months
- Use of medications affecting appetite or body weight within the previous month
- Use of medications affecting eating behavior or mood within the previous month
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active Home-Based tDCSParticipants receive active home-based transcranial direct current stimulation (tDCS) using a wearable wellness scalp stimulation device. Active stimulation delivers 1.0 mA direct current for 20 minutes twice daily for 4 weeks. | Device | Active tDCS |
| Sham Home-Based tDCSParticipants receive sham home-based transcranial direct current stimulation (tDCS) using the same wearable wellness scalp stimulation device. Sham stimulation delivers brief current only at the beginning and end of each session to maintain blinding. | Device | Sham tDCS |
Primary outcome
Change in Appetite Visual Analog Scale Score Before and After Stimulation
Time frame: Immediately before and after the first stimulation session on Days 7, 14, 21, and 28.
Acute change in appetite is assessed using the Appetite Visual Analog Scale (VAS) immediately before and after the first daily stimulation session on Days 7, 14, 21, and 28. The acute effect is defined as the change in Appetite VAS score from immediately before to immediately after stimulation. The Appetite Visual Analog Scale ranges from 0 to 10, with higher scores indicating greater appetite.
Change in Bedtime Appetite Visual Analog Scale Score Over 4 Weeks
Time frame: Daily from Day 1 through Day 28
Chronic change in appetite is assessed using the bedtime Appetite Visual Analog Scale (BT-VAS), measured once daily before bedtime from Day 1 through Day 28. The chronic effect is evaluated based on the change in bedtime Appetite VAS scores over time during the 4-week intervention period. The Appetite Visual Analog Scale ranges from 0 to 10, with higher scores indicating greater appetite.
21 secondary outcomes
Change in Body Weight
Time frame: Baseline to Week 4
Change in Body Mass Index
Time frame: Baseline to Week 4
Change in Body Fat Percentage
Time frame: Baseline to Week 4
Change in Waist Circumference
Time frame: Baseline to Week 4
Change in Skeletal Muscle Mass
Time frame: Baseline to Week 4
Change in Dutch Eating Behavior Questionnaire Scores
Time frame: Baseline to Week 4
Change in Reward-Based Eating Drive Scale Score
Time frame: Baseline to Week 4
Change in General Food Cravings Questionnaire-Trait Score
Time frame: Baseline to Week 4
General Food Cravings Questionnaire-State Score
Time frame: Days 7, 14, 21, and 28
Change in Behavioral Inhibition System Score
Time frame: Baseline to Week 4
Change in Behavioral Activation System Scores
Time frame: Baseline to Week 4
Change in Eating Expectancy Inventory (EEI) Scores
Time frame: Baseline and Week 4
Change in Anticipated Negative Effects of Junk Food Score
Time frame: Baseline to Week 4
Change in Anticipated Positive Effects of Junk Food Score
Time frame: Baseline to Week 4
Change in Anticipated Negative Effects of Healthy Food Score
Time frame: Baseline to Week 4
Change in Anticipated Positive Effects of Healthy Food Score
Time frame: Baseline to Week 4
Change in Perceived Stress Scale Score
Time frame: Baseline to Week 4
Change in Pittsburgh Sleep Quality Index Score
Time frame: Baseline to Week 4
Change in Beck Depression Inventory-II Score
Time frame: Baseline to Week 4
Change in Beck Anxiety Inventory Score
Time frame: Baseline to Week 4
Change in Binge Eating Scale Score
Time frame: Screening to Week 4
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared because there is no current plan for public or external data sharing. De-identified study data will be used only for the purposes described in the study protocol and approved by the Institutional Review Board (IRB).
Related trials for Appetite
Active, not recruiting
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
Overweight, Obesity
RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Overweight or Obesity
Not yet recruitingPhase 3
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
Overweight or Obesity Without Diabetes
Recruiting
Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10
Healthy Adult
Recruiting
GLycaemic Outcomes With Whey Protein in ageING
Type 2 Diabetes, Appetite Regulation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hyung jin Choi, MD-PhD principal investigator
Seoul National University College of Medicine
Questions about this trial
What is this clinical trial studying?
A study testing Active Home-Based tDCS in people with Appetite and Binge Eating Behaviour, run by Seoul National University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hyun young Noh, MD (+82 1048507697, nhy9175@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Appetite Visual Analog Scale Score Before and After Stimulation (time frame: Immediately before and after the first stimulation session on Days 7, 14, 21, and 28.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.